Answers are grounded in this paper and cite their sources.
In the field of general medicine, class effects, or therapeutic interchangeability, have been declared for several families of drugs including statins, calcium channel blockers and ACE inhibitors. The existence of such class effects enables healthcare payers to negotiate for substantially lower drug prices, thereby reducing financial toxicity, both at an individual and societal levels. Until now, the existence of class effects in oncology has been considered rare. Here, we review evidence from clinical trials that supports the existence of class effects for several types of anticancer drugs. These class effects in oncology should be exploited to reduce healthcare costs.
No takes yet. Share an insight, caveat, or question.
Goldstein et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: